Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 5/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19627121 | 0.87 | SLC6A4 (0.39) | SLC6A4OPRK1TRPA1TRPV1KDR | |
| SCHEMBL19627118 | 0.79 | SLC6A4 (0.40) | SLC6A4OPRM1OPRK1TRPA1TRPV1 | |
| SCHEMBL17793495 | 0.77 | SLC6A4 (0.63) | SLC6A4OPRM1OPRK1CYP17A1CYP3A4 | |
| SCHEMBL26322891 | 0.76 | SLC6A4 (0.54) | SLC6A4OPRM1OPRK1ESR1ESR2 | |
| SCHEMBL19627106 | 0.72 | SLC6A4 (0.39) | SLC6A4OPRM1OPRK1TRPA1TRPV1 | |
| SCHEMBL26927698 | 0.69 | TRPA1 (0.35) | SLC6A4OPRM1OPRK1TRPA1TRPV1 | |
| SCHEMBL19627107 | 0.69 | TRPA1 (0.31) | SLC6A4OPRM1OPRK1TRPA1TRPV1 | |
| SCHEMBL19627114 | 0.68 | CYP3A4 (0.41) | SLC6A4OPRK1TRPA1TRPV1KDR | |
| SCHEMBL19627132 | 0.68 | SLC6A4 (0.31) | SLC6A4 | |
| SCHEMBL19627101 | 0.68 | TSHR (0.32) | TRPA1TRPV1KDRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840541-B2 | Opioid receptor modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230271976-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-31 | — | — | US | disclosed |
| US-20170334923-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334923-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRD1 | SLC6A4 323/4885OPRM1 1/4885OPRK1 4/4885 |
| US-20230271976-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRD1 | SLC6A4 305/4885OPRM1 1/4885OPRK1 4/4885 |
| US-11840541-B2 | Opioid receptor modulators | OPRM1, OPRL1, OPRD1 | SLC6A4 323/4885OPRM1 1/4885OPRK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.